Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi
Status:
Completed
Trial end date:
2018-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if there is a benefit to taking
trimethoprim-sulfamethoxazole (TS) as prophylaxis among HIV positive adults who have viral
load suppression and a good clinical response on anti-retroviral therapy (ART). If there is a
benefit, then is it due to antimalarial or antibacterial properties.
The investigators hypothesize that there will be a long-term benefit on survival and disease
control in the context of prophylaxis and that the benefit will largely be attributed to
prevention of malaria. The main study hypothesis is that 1)TS and chloroquine (CQ) will
decrease the rates of morbidity and mortality among adults after 6 or more months of ART and
2) CQ prophylaxis will be associated with more prolonged viral suppression and higher CD4
cell counts than TS prophylaxis or no prophylaxis.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Chloroquine Chloroquine diphosphate Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination